Q2
VRTX — Q2 2026 Financial Report Analysis
Vertex's Q2 2026 revenue rose 12% to $3.33B as ALYFTREK took over from TRIKAFTA in cystic fibrosis, but a 37% jump in launch spending held EPS growth to 8% ($4.31); 2026 revenue guidance was raised to $13.1–13.2B ahead of the ~$10B Crinetics deal.